You are here

Our science / Clinical Trials / Find a Trial / NCT00930059

A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease

Back to Search Print Save as PDF Bookmark Trial

NCT00930059

Last updated on February 17, 2019
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Northport, Alabama, 35476 United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Alzheimer's Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
55-85 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Mild to moderate Alzheimer's disease (MMSE 14-26)

- Good general health (such controlled conditions as Type 2 diabetes and hypertension
allowed)

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Use of acetylcholinesterase inhibitors (donepezil, rivastigmine, or galantamine) or
memantine within 12 weeks of the start of the study

- Significant cardiovascular disease in the past 6 months

- Illness other than Alzheimer's disease that could contribute to cognitive impairment

- History of stroke or seizure disorder

NCT00930059
Pfizer
Completed
A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Based on your search, you may also be interested in

Alzheimer's Disease
A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI
NCT00483028
All Genders
55+
Years
Multiple Sites
Alzheimer's Disease
Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease
NCT00959192
All Genders
50+
Years
Multiple Sites
Alzheimer's Disease, Huntington's Disease
A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers
NCT00931073
All Genders
18+
Years
Kalamazoo, Michigan
Alzheimer's Disease
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
NCT01369225
All Genders
50+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now